These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11443196)

  • 1. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification.
    Sánchez-Quesada JL; Pérez A; Caixàs A; Rigla M; Payés A; Benítez S; Ordóñez-Llanos J
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3243-9. PubMed ID: 11443196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM.
    Reaven PD; Herold DA; Barnett J; Edelman S
    Diabetes Care; 1995 Jun; 18(6):807-16. PubMed ID: 7555507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control.
    Benítez S; Pérez A; Sánchez-Quesada JL; Wagner AM; Rigla M; Arcelus R; Jorba O; Ordóñez-Llanos J
    Diabetes Metab Res Rev; 2007 Jan; 23(1):26-34. PubMed ID: 16634114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of LDL+VLDL oxidizability and hyperglycemia on blood cholesterol, phospholipid and triglyceride levels in type-I diabetic patients.
    Jain SK; McVie R; Meachum ZD; Smith T
    Atherosclerosis; 2000 Mar; 149(1):69-73. PubMed ID: 10704616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition?
    Moro E; Alessandrini P; Zambon C; Pianetti S; Pais M; Cazzolato G; Bon GB
    Diabet Med; 1999 Aug; 16(8):663-9. PubMed ID: 10477211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.
    Julier K; Mackness MI; Dean JD; Durrington PN
    Diabet Med; 1999 May; 16(5):415-23. PubMed ID: 10342342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients.
    Manzato E; Zambon A; Zambon S; Nosadini R; Doria A; Marin R; Crepaldi G
    Acta Diabetol; 1993; 30(1):11-6. PubMed ID: 8329725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation.
    Jenkins AJ; Klein RL; Chassereau CN; Hermayer KL; Lopes-Virella MF
    Diabetes; 1996 Jun; 45(6):762-7. PubMed ID: 8635650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications.
    Kesavulu MM; Giri R; Kameswara Rao B; Apparao C
    Diabetes Metab; 2000 Nov; 26(5):387-92. PubMed ID: 11119018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperketonemia (acetoacetate) increases the oxidizability of LDL + VLDL in Type-I diabetic patients.
    Jain SK; McVie R; Jaramillo JJ; Chen Y
    Free Radic Biol Med; 1998 Jan; 24(1):175-81. PubMed ID: 9436628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
    Koba S; Hirano T; Yoshino G; Sakai K; Sakaue T; Adachi M; Katagiri T
    Atherosclerosis; 2002 Jan; 160(1):249-56. PubMed ID: 11755944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients.
    Rivellese AA; Patti L; Romano G; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4188-92. PubMed ID: 11095452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control.
    Pérez A; Wägner AM; Carreras G; Giménez G; Sánchez-Quesada JL; Rigla M; Gómez-Gerique JA; Pou JM; de Leiva A
    Arch Intern Med; 2000 Oct; 160(18):2756-62. PubMed ID: 11025785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein compositional abnormalities in type I diabetes: effect of improved glycaemic control.
    Pérez A; Caixàs A; Carreras G; Mauricio D; Pou JM; Serrat J; Gómez-Gerique J; de Leiva A
    Diabetes Res Clin Pract; 1997 May; 36(2):83-90. PubMed ID: 9229192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation.
    Moro E; Zambon C; Pianetti S; Cazzolato G; Pais M; Bittolo Bon G
    Acta Diabetol; 1998 Oct; 35(3):161-4. PubMed ID: 9840454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus.
    Yegin A; Ozben T; Yegin H
    Int J Clin Lab Res; 1995; 25(3):157-61. PubMed ID: 8562980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
    Bavirti S; Ghanaat F; Tayek JA
    Endocr Pract; 2003; 9(6):487-93. PubMed ID: 14715475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
    Harada N; Kashiwagi A; Nishio Y; Kikkawa R
    Diabetes Res Clin Pract; 1999 Feb; 43(2):111-20. PubMed ID: 10221663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein abnormalities in well-treated type II diabetic patients.
    Manzato E; Zambon A; Lapolla A; Zambon S; Braghetto L; Crepaldi G; Fedele D
    Diabetes Care; 1993 Feb; 16(2):469-75. PubMed ID: 8432219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
    Sánchez-Quesada JL; Vinagre I; de Juan-Franco E; Sánchez-Hernández J; Blanco-Vaca F; Ordóñez-Llanos J; Pérez A
    Am J Cardiol; 2012 Jul; 110(1):67-71. PubMed ID: 22481012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.